Pulse Biosciences, Inc.

Headquartered in Miami, Florida, Pulse Biosciences, Inc. (NASDAQ: PLSE) pioneers the field of bioelectric medicine. Since its founding in 2014, the firm has developed innovative therapies that use electrical energy to clear targeted cells without damaging surrounding tissue.

The company bases its entire product portfolio on proprietary Nanosecond Pulsed-Field Ablation (nsPFA) technology. In contrast to legacy thermal ablation techniques that can cook adjacent structures, this non-thermal approach delivers ultra-short electrical pulses to trigger regulated cell death. Through this unique mechanism, the firm offers specialized devices like the nPulse Console, the nPulse Vybrance system for surgical soft tissue, and the nPulse Cardiac Catheter System for treating atrial fibrillation.

At the start of 2026, the organization narrowed its strategic focus onto electrophysiology following landmark clinical trial data. During a major medical symposium in February, investigators revealed that the company’s cardiac catheter achieved a 96% procedural success rate at twelve months. On top of this clinical momentum, the firm secured regulatory approval and enrolled its first patients in the NANOPULSE-AF pivotal U.S. study. In an effort to accelerate global commercial planning, the board appointed industry veteran Liane Teplitsky as Chief Operating Officer.

In order to demonstrate absolute conviction in this pipeline shift, the chief executive officer completed a significant open-market stock purchase in May 2026. Armed with a healthy cash balance to fund its ongoing trials, management expects to complete U.S. study enrollment by the beginning of the fourth quarter. By combining rapid procedural workflows with unique electrode designs, Pulse Biosciences continues to challenge legacy device makers and redefine the standards of cardiac care.